Please use this identifier to cite or link to this item:
https://ah.lib.nccu.edu.tw/handle/140.119/135854
題名: | Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. | 作者: | 陳秉訓 Chen, Ping-Hsun |
貢獻者: | 科管智財所 | 關鍵詞: | Tirosint ; indefiniteness ; new abbreviated drug application ; semi-liquid ; half-liquid | 日期: | Dec-2020 | 上傳時間: | 17-Jun-2021 | 摘要: | IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc., 966 F.3d 1374 (Fed. Cir. 2020), shows a case of inaccurate translation leading the court to find the asserted claims invalid. The disputed term “half-liquid” was found unclear in terms of whether pastes and gels should fall within or be excluded from the patentee`s construction of “half-liquid.” This article examines the IBSA case and argues that there could have been a chance to avoid such mistake. This article also demonstrates that the translation error is not correctable under 35 U.S.C. § 255. | 關聯: | Biotechnology Law Report, Vol.39, No.6, pp.452-457 | 資料類型: | article | DOI: | https://doi.org/10.1089/blr.2020.29208.phc |
Appears in Collections: | 期刊論文 |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.